Preclinical work demonstrating greater efficacy of CENPE, Eg5, and KIF18A inhibitors in aneuploid, tetraploid, and CIN-positive cancer models supports this concept [74,134,142,145]. The gene discussed is KIF18A; the disease is cancer.